News and Announcements
OMX Solutions awarded travel grant to attend “Go to Market in the USA” Program in Minnesota this October
- Published August 14, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OMX-Solutions have recently been awarded a travel grant to attend the “Go to Market in the USA Program” to be held in Minneapolis USA in October. The program supported and sponsored by the BioMelbourne Network, Launch Vic and the Medical Alley Assoc (USA), OMX-Solutions very gratefully received the announcement and additional support to attend this program. The program has involved some fabulous and engaging presentations from leading reimbursement experts in the health and MedTech industry from the USA in Melbourne over the past few months. The opportunity for OMX-Solutions to first-hand visit one of the USA MedTech heartlands ties in closely with the companies plans to commence the work to enter both the USA and the UK/Euro markets as part of the companies expansion plans.
OMX-Solutions looks forward to attending this program and using the experience to further develop and enhance our strategy and payment models for our range of fully customized OMS implants and devices. OMX-Solutions would also like to thank BioMelbourne Network, Launch Vic and the Medical Alley Assoc. for their support and making these events possible.
About OMX Solutions
OMX Solutions creates breakthrough medical devices for Craniomaxillofacial surgery, helping patients requiring implants due to jaw arthritis, insufficient bone to fit dental implants, cancer and trauma victims requiring jaw and bone replacement. Utilising our proprietary digital planning processes and 3D printed additive manufacturing we address global markets with proven surgical products and devices that are game-changers in our field.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
